Crohn’s Disease Therapeutics Market Projected to Reach USD 11.16 Billion by 2030

Advancements in Non-Surgical Treatments and Rising Disease Prevalence Drive Market Expansion

The Crohn’s Disease Therapeutics Market Growth is poised for significant growth, with projections indicating a rise from USD 7.47 billion in 2023 to approximately USD 11.16 billion by 2030. This represents a Compound Annual Growth Rate (CAGR) of 5.9% over the forecast period. The surge is primarily attributed to the increasing prevalence of Crohn's disease and continuous advancements in therapeutic options.

Important points to note are: Click here to obtain a PDF sample copy of this report : https://www.maximizemarketresearch.com/request-sample/121644/

Market Definition and Estimation

Crohn's disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, leading to symptoms such as abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammation often penetrates deep into the layers of affected bowel tissue, resulting in debilitating and sometimes life-threatening complications.

The market valuation reflects the growing demand for effective treatments, driven by the rising incidence of Crohn's disease globally. Factors such as industrialization, environmental changes, dietary shifts, smoking, and genetic predispositions have contributed to this increase, particularly in developing countries. According to the Centers for Disease Control and Prevention (CDC), approximately 1.8 million Americans are affected by IBD annually.

Market Growth Drivers and Opportunities

Several key factors are propelling the growth of the Crohn’s Disease Therapeutics Market:

Rising Disease Prevalence: The increasing number of Crohn's disease cases worldwide necessitates the development and availability of effective therapeutic options.

Advancements in Non-Surgical Treatments: Innovations in non-surgical therapies, including the development of biosimilars and novel biological agents, offer effective treatment alternatives with improved safety profiles. Biosimilars, in particular, provide cost-effective options, enhancing patient access to advanced therapies.

Strategic Collaborations and Acquisitions: Major pharmaceutical companies are engaging in partnerships and acquisitions to bolster their therapeutic portfolios. For instance, Eli Lilly's acquisition of Morphic Holding for $3.2 billion aims to enhance its capabilities in producing treatments for inflammatory bowel diseases, including Crohn's disease.

Regulatory Approvals of New Therapies: The approval of new therapeutic agents expands the treatment landscape. Eli Lilly's Omvoh, for example, received U.S. FDA approval for treating moderate-to-severe Crohn's disease in adults, demonstrating significant efficacy in clinical trials.

Details insights on this market, request for methodology here : https://www.maximizemarketresearch.com/request-sample/121644/


Segmentation Analysis

The Crohn’s Disease Therapeutics Market is segmented based on therapeutic type and region.

By Therapeutic Type:
Non-Surgical Treatments: This segment dominates the market, accounting for 49% of the share in 2023. It includes:

Anti-Inflammatory Agents: Serving as the first line of treatment, these agents effectively reduce inflammation and are widely prescribed.
Immune System Suppressors: Expected to grow at a CAGR of 3.2%, these suppressors have demonstrated safety and efficacy, leading to reduced mortality rates, fewer hospitalizations, and improved patient quality of life. Companies like Genentech Inc. are developing immune system suppressors, such as etrolizumab, which has shown promise in clinical trials.
Antibiotics: Utilized to treat infections that may trigger or exacerbate symptoms, antibiotics are a critical component of non-surgical management.
Others: This category encompasses various supportive therapies aimed at symptom management and improving patient well-being.
Surgical Treatments: While non-surgical options are preferred, surgery becomes necessary for patients who do not respond to medical therapy or develop complications. Surgical interventions may involve removing damaged portions of the digestive tract or addressing obstructions and fistulas.

Regional Analysis

North America: In 2023, North America led the global market in revenue. The region's growth is driven by a well-established R&D infrastructure, the introduction of novel therapies, and a high prevalence of Crohn's disease. The United States, in particular, has a significant patient population, with approximately 1.6 million Americans affected by IBD annually. The robust healthcare infrastructure and proactive development of new treatment options further support market expansion.

Europe: Countries like Germany and the United Kingdom are witnessing increased Crohn's disease cases, attributed to factors such as dietary habits and environmental influences. The European market benefits from strong healthcare systems and ongoing research collaborations aimed at developing advanced therapeutics.

Asia-Pacific: This region is expected to experience substantial growth due to rising disease awareness, improving healthcare facilities, and increasing adoption of advanced treatments. Countries like Japan, China, and India are focusing on enhancing their healthcare infrastructure to manage the growing burden of Crohn's disease.

Browse Full report : https://www.maximizemarketresearch.com/market-report/crohns-disease-therapeutics-market/121644/


Competitive Analysis

The Crohn’s Disease Therapeutics Market is characterized by the presence of key players striving for innovation and market leadership:

Eli Lilly: With the recent FDA approval of Omvoh for moderate-to-severe Crohn's disease, Eli Lilly has strengthened its position in the market. The acquisition of Morphic Holding further underscores its commitment to expanding its therapeutic offerings in the IBD sector.

Teva Pharmaceutical Industries and Sanofi: This partnership has yielded promising results with their drug duvakitug. Phase 2b studies demonstrated significant clinical remission in patients with ulcerative colitis and Crohn's disease, positioning the drug as a potential best-in-class therapy. Plans for Phase 3 trials are underway, aiming to bring this innovative treatment to market.

Johnson & Johnson: The company's biologic therapy, Stelara, has been approved for treating Crohn's disease, offering patients an alternative with a unique mechanism of action. Ongoing research and development efforts continue to enhance their gastrointestinal therapeutic portfolio.

Pfizer Inc.: Actively engaged in developing novel therapies, Pfizer focuses on small molecules and biologics targeting specific pathways involved in the inflammatory process of Crohn's disease.

AbbVie Inc.: Known for its TNF inhibitor, Humira, AbbVie remains a significant player in the market. The company is also investing in next-generation therapies to address unmet needs in Crohn's disease treatment.

Conclusion

The global Crohn’s Disease Therapeutics Market is on a trajectory of robust growth, driven by increasing disease prevalence, advancements in non-surgical treatments, and strategic industry collaborations. As pharmaceutical companies continue to innovate and expand their therapeutic portfolios, patients worldwide can anticipate improved access to effective treatments, enhancing quality of life and disease management outcomes.

Related Reports :

Global POC Lipid Testing Market https://www.maximizemarketresearch.com/market-report/global-poc-lipid-testing-market/112829/

Middle East Blood Glucose Monitoring System Market https://www.maximizemarketresearch.com/market-report/blood-glucose-monitoring-system-market-middle-east/1669/

Global Hemifacial Spasm Treatment Market https://www.maximizemarketresearch.com/market-report/hemifacial-spasm-treatment-market/72812/

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[email protected]

+91 9607365656